Q BioMed Inc. (QBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 21, 2025, 4:00 PM EDT
Q BioMed Revenue
Q BioMed had revenue of $209.29K in the twelve months ending February 28, 2023, down -22.67% year-over-year. In the fiscal year ending November 30, 2022, Q BioMed had annual revenue of $284.35K with 45.38% growth.
Revenue (ttm)
209.29K
Revenue Growth
-22.67%
P/S Ratio
0.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
145.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2022 | 284.35K | 88.76K | 45.38% |
| Nov 30, 2021 | 195.60K | 165.60K | 551.99% |
| Nov 30, 2020 | 30.00K | - | - |
| Nov 30, 2019 | - | - | - |
| Nov 30, 2018 | - | - | - |
| Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.09M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Q BioMed News
- 2 years ago - Q BioMed Inc. Provides Update to Shareholders - PRNewsWire
- 2 years ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe - PRNewsWire
- 2 years ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office - PRNewsWire
- 3 years ago - Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. - PRNewsWire
- 3 years ago - Q BIOMED PROVIDES SHAREHOLDER UPDATE - PRNewsWire
- 3 years ago - Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER - PRNewsWire
- 3 years ago - Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. - Accesswire
- 3 years ago - Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets - PRNewsWire